{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:25Z","timestamp":1792839745701,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","gastrojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1053\/j.gastro.2018.06.042","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T22:27:12Z","timestamp":1530138432000},"page":"1120-1127.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3\u00a0Infection\u00a0and Cirrhosis"],"prefix":"10.1053","volume":"155","author":[{"given":"Rafael","family":"Esteban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Turnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Enrique","family":"Morano Amado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Pascasio Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Riveiro-Barciela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McNabb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Camus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 Suppl","key":"10.1053\/j.gastro.2018.06.042_bib1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.06.042_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib5","unstructured":"American Association for the Study of Liver Diseases (AASLD), Infectious Disease Society of America (IDSA). HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: https:\/\/hcvguidelines.org\/. Accessed March 15,\u00a02018."},{"key":"10.1053\/j.gastro.2018.06.042_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/jvh.12168","article-title":"Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3","volume":"20","author":"Tapper","year":"2013","journal-title":"J\u00a0Viral Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib7","unstructured":"Gilead Sciences Inc. EPCLUSA (Sofosbuvir and Velpatasvir) Tablets, for Oral Use. US Prescribing Information. Foster City, CA: Gilead Sciences; revised August\u00a02017."},{"key":"10.1053\/j.gastro.2018.06.042_bib8","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.06.042_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.06.042_bib10","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/cid\/ciw496","article-title":"Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from Astral-2 and -3 clinical trials","volume":"63","author":"Younossi","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.gastro.2018.06.042_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.14423","article-title":"Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-na\u00efve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3","volume":"47","author":"Younossi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.06.042_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/liv.13534","article-title":"Sofosbuvir\/velpatasvir in patients with hepatitis C virus genotypes 1\u20136 and compensated cirrhosis or advanced fibrosis","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.06.042_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.06.042_bib14","first-page":"1","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib15","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.06.042_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"von Felden","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.06.042_bib17","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2018.06.042_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","article-title":"Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial","volume":"163","author":"Pianko","year":"2015","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.06.042_bib19","article-title":"Prevalence of Pretreatment NS5A and NS5B NI-Resistance Associated Substitutions in HCV-Infected Patients Enrolled in Clinical Trials in Asia","volume":"11","author":"Wei","year":"2017","journal-title":"Hepatol Int"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.06.042_bib20","article-title":"Natural NS3, NS5A, and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to HS5A inhibitors","volume":"63","author":"Cento","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.06.042_bib21","unstructured":"Gilead Sciences Ireland UC. Epclusa 400 mg\/100 mg Film Coated Tablets. Summary of Product Characteristics (SmPC). Foster City, CA: Gilead Sciences; revised May\u00a02017."},{"key":"10.1053\/j.gastro.2018.06.042_bib22","unstructured":"Hoffmann-Roche Inc. COPEGUS (Ribavirin) Tablets, for Oral Use. US Prescribing Information. Revised August\u00a02015."},{"key":"10.1053\/j.gastro.2018.06.042_bib23","article-title":"Roche Products Limited. Copegus (Ribavirin) 400 mg Film-Coated Tablets for Oral Use. Summary of Product Characteristics","year":"2015","journal-title":"Revised February"},{"key":"10.1053\/j.gastro.2018.06.042_bib24","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","article-title":"Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)","volume":"63","author":"Leroy","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.06.042_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.06.042_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.06.042_bib27","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/206453\/1\/WHO_HIV_2016.04_eng.pdf?ua=1. Published May 2016. Accessed May 17,\u00a02018."},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.06.042_bib28","article-title":"Marked reduction in the prevalence of hepatitis C viremia among people who inject drugs during 2nd year of the Treatment as Prevention (TraP HepC) program in Iceland","volume":"68","author":"Tyrfingsson","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.06.042_bib29","volume":"68","author":"Mangia","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.06.042_bib30","article-title":"The evolution of treatment for HCV genotype 3 (GT3) infected patients with advanced fibrosis\/cirrhosis over time. Presented at the 53rd Annual Meeting of the European Association for the Study of the Liver April 11\u201315, 2018, Paris, France","volume":"68","author":"Mangia","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.06.042_bib31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518346845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518346845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T18:39:12Z","timestamp":1544812752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508518346845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0016508518346845"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.06.042","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3\u00a0Infection\u00a0and Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}